Novel cell and gene therapy development continues to expand. Six FDA-approved autologous chimeric antigen receptor T-cell (CAR-T) therapies are on the market in the U.S., all for treating hematologic malignancies, including B-cell acute lymphoblastic leukemia, B-cell non-Hodgkin lymphoma, multiple myeloma, follicular lymphoma, and mantle cell lymphoma.1,2 However, allogeneic cell and gene therapy development has started…